In conclusion, this case report describes a patient with osimertinib‐induced ulcerative colitis, successfully managed with mesalazine, suggesting a possible association between the EGFR inhibitor and ulcerative colitis exacerbation. Here, EGFR is linked to ulcerative colitis.